PL378136A1 - Pirymidyny i triazyny hamujące replikacją wirusa HIV - Google Patents
Pirymidyny i triazyny hamujące replikacją wirusa HIVInfo
- Publication number
- PL378136A1 PL378136A1 PL378136A PL37813604A PL378136A1 PL 378136 A1 PL378136 A1 PL 378136A1 PL 378136 A PL378136 A PL 378136A PL 37813604 A PL37813604 A PL 37813604A PL 378136 A1 PL378136 A1 PL 378136A1
- Authority
- PL
- Poland
- Prior art keywords
- hiv replication
- triazines
- replication inhibiting
- inhibiting pyrimidines
- pyrimidines
- Prior art date
Links
- 230000010076 replication Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000003918 triazines Chemical class 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- -1 amine compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Przedmiotem wynalazku są inhibitory replikacji wirusa HIV o wzorze (I), ich N-tlenki, ich sole addycyjne dopuszczone do stosowania w farmacji, ich czwartorzędowe związki aminowe oraz ich stereochemiczne postacie izomeryczne, ich zastosowanie w medycynie, sposoby ich wytwarzania oraz zawierające je kompozycje farmaceutyczne.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03100411.2 | 2003-02-20 | ||
| EP03100411 | 2003-02-20 | ||
| US47501203P | 2003-06-02 | 2003-06-02 | |
| US60/475,012 | 2003-06-02 | ||
| PCT/EP2004/050177 WO2004074262A1 (en) | 2003-02-20 | 2004-02-20 | Hiv replication inhibiting pyrimidines and triazines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL378136A1 true PL378136A1 (pl) | 2006-03-06 |
| PL227295B1 PL227295B1 (pl) | 2017-11-30 |
Family
ID=32910137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378064A PL226954B1 (pl) | 2003-02-20 | 2004-02-20 | Pochodna pirymidyny hamujaca replikacje wirusa HIV, kompozycja farmaceutyczna iprodukt jazawierajacy oraz sposób wytwarzania pochodnej pirymidyny |
| PL378136A PL227295B1 (pl) | 2003-02-20 | 2004-02-20 | Pochodna pirymidyny hamujaca replikacje wirusa HIV |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL378064A PL226954B1 (pl) | 2003-02-20 | 2004-02-20 | Pochodna pirymidyny hamujaca replikacje wirusa HIV, kompozycja farmaceutyczna iprodukt jazawierajacy oraz sposób wytwarzania pochodnej pirymidyny |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US7442705B2 (pl) |
| EP (2) | EP1603887B1 (pl) |
| JP (2) | JP4586013B2 (pl) |
| KR (2) | KR20050094896A (pl) |
| CN (2) | CN1751031B (pl) |
| AP (1) | AP2005003373A0 (pl) |
| AR (2) | AR044500A1 (pl) |
| AT (2) | ATE506353T1 (pl) |
| AU (2) | AU2004213187B2 (pl) |
| BR (2) | BRPI0407732A (pl) |
| CA (2) | CA2516699C (pl) |
| CL (2) | CL2004000306A1 (pl) |
| CY (1) | CY1106788T1 (pl) |
| DE (2) | DE602004006383T2 (pl) |
| DK (1) | DK1597238T3 (pl) |
| EA (2) | EA011256B1 (pl) |
| ES (1) | ES2287734T3 (pl) |
| HR (2) | HRP20050820A2 (pl) |
| IL (2) | IL169596A (pl) |
| MX (2) | MXPA05008866A (pl) |
| MY (1) | MY138308A (pl) |
| NO (2) | NO20054312L (pl) |
| NZ (2) | NZ541601A (pl) |
| PL (2) | PL226954B1 (pl) |
| PT (1) | PT1597238E (pl) |
| TW (2) | TW200510339A (pl) |
| WO (2) | WO2004074261A1 (pl) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ATE451104T1 (de) | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
| CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| US7456176B2 (en) | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US7652051B2 (en) | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| WO2006068770A1 (en) | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| NZ592990A (en) | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CN101573342A (zh) * | 2006-12-29 | 2009-11-04 | 泰博特克药品有限公司 | 抑制hiv的5,6-取代的嘧啶类化合物 |
| KR20090094073A (ko) * | 2006-12-29 | 2009-09-03 | 티보텍 파마슈티칼즈 리미티드 | Ｈｉｖ를 억제하는 6-치환된 피리미딘 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PL2300013T5 (pl) | 2008-05-21 | 2025-04-28 | Takeda Pharmaceutical Company Limited | Pochodne fosforu jako inhibitor kinazy |
| US7737157B2 (en) * | 2008-08-29 | 2010-06-15 | Hutchison Medipharma Enterprises Limited | Pyrimidine compounds |
| CN102216276A (zh) | 2008-09-11 | 2011-10-12 | 辉瑞大药厂 | 取代的杂芳基物 |
| AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| JP5086480B2 (ja) | 2009-03-11 | 2012-11-28 | ファイザー・インク | グルコキナーゼ活性化剤として使用されるベンゾフラニル誘導体 |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| WO2012135641A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center And Research Institute | Aurora kinase inhibitors and methods of making and using thereof |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
| GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| EP3492462B1 (en) * | 2016-07-26 | 2023-08-30 | Shenzhen TargetRx, Inc. | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
| CN106749203B (zh) * | 2016-11-28 | 2020-04-10 | 洛阳聚慧医药科技有限公司 | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| EP4295846A3 (en) | 2019-05-10 | 2024-02-28 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| CA3143489A1 (en) | 2019-06-17 | 2020-12-24 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| CZ154398A3 (cs) | 1995-11-23 | 1998-08-12 | Janssen Pharmaceutica N.V. | Pevné směsi cyklodextrinů připravené vytlačováním taveniny |
| NO311614B1 (no) * | 1996-10-01 | 2001-12-17 | Janssen Pharmaceutica Nv | Substituerte diamino-1,3,5-triazinderivater |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0945447A1 (en) * | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
| ATE232521T1 (de) * | 1998-03-27 | 2003-02-15 | Janssen Pharmaceutica Nv | Hiv hemmende pyrimidin derivate |
| AU762523C (en) * | 1998-11-10 | 2004-02-12 | Janssen Pharmaceutica N.V. | HIV replication inhibiting pyrimidines |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| CN1348370A (zh) | 1999-04-15 | 2002-05-08 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| DE60025837T2 (de) * | 1999-09-24 | 2006-11-02 | Janssen Pharmaceutica N.V. | Antivirale feste dispersionen |
| CA2386218A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| JP5230050B2 (ja) | 2000-05-08 | 2013-07-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｈｉｖ複製阻害剤 |
| AU2002216650A1 (en) * | 2000-10-31 | 2002-05-15 | Lynn Bonham | Triazine derivatives as lpaat-b inhibitors and uses thereof |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| KR100875362B1 (ko) * | 2002-02-05 | 2008-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
| AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| CN1665789A (zh) * | 2002-06-28 | 2005-09-07 | 山之内制药株式会社 | 二氨基嘧啶酰胺衍生物 |
| ATE451104T1 (de) * | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
| CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
-
2004
- 2004-02-19 CL CL200400306A patent/CL2004000306A1/es unknown
- 2004-02-19 CL CL200400303A patent/CL2004000303A1/es unknown
- 2004-02-20 BR BRPI0407732-6A patent/BRPI0407732A/pt not_active Application Discontinuation
- 2004-02-20 KR KR1020057014231A patent/KR20050094896A/ko not_active Ceased
- 2004-02-20 DK DK04737252T patent/DK1597238T3/da active
- 2004-02-20 ES ES04737252T patent/ES2287734T3/es not_active Expired - Lifetime
- 2004-02-20 TW TW093104175A patent/TW200510339A/zh unknown
- 2004-02-20 AP AP2005003373A patent/AP2005003373A0/xx unknown
- 2004-02-20 KR KR1020057014648A patent/KR20050099994A/ko not_active Ceased
- 2004-02-20 MX MXPA05008866A patent/MXPA05008866A/es active IP Right Grant
- 2004-02-20 AR ARP040100549A patent/AR044500A1/es not_active Application Discontinuation
- 2004-02-20 AU AU2004213187A patent/AU2004213187B2/en not_active Ceased
- 2004-02-20 EP EP04737251A patent/EP1603887B1/en not_active Expired - Lifetime
- 2004-02-20 MX MXPA05008867A patent/MXPA05008867A/es active IP Right Grant
- 2004-02-20 DE DE602004006383T patent/DE602004006383T2/de not_active Expired - Lifetime
- 2004-02-20 US US10/545,358 patent/US7442705B2/en not_active Expired - Lifetime
- 2004-02-20 DE DE602004032321T patent/DE602004032321D1/de not_active Expired - Lifetime
- 2004-02-20 BR BRPI0407741A patent/BRPI0407741B8/pt not_active IP Right Cessation
- 2004-02-20 JP JP2006502041A patent/JP4586013B2/ja not_active Expired - Fee Related
- 2004-02-20 AT AT04737251T patent/ATE506353T1/de not_active IP Right Cessation
- 2004-02-20 CA CA2516699A patent/CA2516699C/en not_active Expired - Fee Related
- 2004-02-20 NZ NZ541601A patent/NZ541601A/en unknown
- 2004-02-20 AR ARP040100548A patent/AR044499A1/es not_active Application Discontinuation
- 2004-02-20 HR HR20050820A patent/HRP20050820A2/xx not_active Application Discontinuation
- 2004-02-20 AU AU2004213186A patent/AU2004213186B2/en not_active Ceased
- 2004-02-20 AT AT04737252T patent/ATE361915T1/de not_active IP Right Cessation
- 2004-02-20 PL PL378064A patent/PL226954B1/pl unknown
- 2004-02-20 HR HR20050821A patent/HRP20050821A2/xx not_active Application Discontinuation
- 2004-02-20 PT PT04737252T patent/PT1597238E/pt unknown
- 2004-02-20 CA CA2516589A patent/CA2516589C/en not_active Expired - Fee Related
- 2004-02-20 WO PCT/EP2004/050175 patent/WO2004074261A1/en not_active Ceased
- 2004-02-20 JP JP2006502042A patent/JP4586014B2/ja not_active Expired - Fee Related
- 2004-02-20 MY MYPI20040575A patent/MY138308A/en unknown
- 2004-02-20 US US10/545,719 patent/US7585870B2/en not_active Expired - Lifetime
- 2004-02-20 EA EA200501327A patent/EA011256B1/ru not_active IP Right Cessation
- 2004-02-20 CN CN2004800043209A patent/CN1751031B/zh not_active Expired - Fee Related
- 2004-02-20 EA EA200501326A patent/EA010423B1/ru not_active IP Right Cessation
- 2004-02-20 PL PL378136A patent/PL227295B1/pl unknown
- 2004-02-20 CN CNB2004800043162A patent/CN100572364C/zh not_active Expired - Fee Related
- 2004-02-20 EP EP04737252A patent/EP1597238B1/en not_active Expired - Lifetime
- 2004-02-20 TW TW093104173A patent/TW200500346A/zh unknown
- 2004-02-20 WO PCT/EP2004/050177 patent/WO2004074262A1/en not_active Ceased
- 2004-02-20 NZ NZ542428A patent/NZ542428A/en unknown
-
2005
- 2005-07-07 IL IL169596A patent/IL169596A/en active IP Right Grant
- 2005-07-12 IL IL169647A patent/IL169647A/en active IP Right Grant
- 2005-09-19 NO NO20054312A patent/NO20054312L/no not_active Application Discontinuation
- 2005-09-19 NO NO20054311A patent/NO20054311L/no not_active Application Discontinuation
-
2007
- 2007-08-03 CY CY20071101039T patent/CY1106788T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL378064A1 (pl) | Pirymidyny i triazyny hamujące replikację wirusa HIV | |
| MX2009011964A (es) | Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico. | |
| SE0202463D0 (sv) | Novel compounds | |
| PL378107A1 (pl) | 1,2,4-triazyny hamujące HIV | |
| MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
| NO20060001L (no) | Nye P2X7-reseptorantagonister og deres anvendelse | |
| BR0213562A (pt) | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna | |
| NO20085087L (no) | Nye heterocykliske forbindelser | |
| DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
| DK1427708T3 (da) | Amino-phthalazinon-derivater som kinase-inhibitorer, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger der indeholder det samme | |
| BRPI0606313A2 (pt) | derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia | |
| TNSN06411A1 (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| MEP25908A (bs) | Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitor kinaze | |
| MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
| MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
| SE0400284D0 (sv) | Novel compounds | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
| BR0316950A (pt) | Derivados de indazol como antagonistas de crf | |
| MX2009011059A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
| DK1673354T3 (da) | Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister | |
| TW200628153A (en) | Novel compounds |